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LETTERS TO THE EDITOR
Mechanism of Protection Against
Vascular Smoking-Induced
Changes by Hormone Replacement Therapy
I read with interest Teede et al.’s (1) report that hormone
replacement therapy (HRT) protects against smoking-induced
changes that favor ischemic heart disease (IHD). The ability of one
agent to prevent IHD (HRT) to protect against another risk factor
(smoking) raises basic issues about the prevention of IHD. The
standard prevention of IHD is based on correcting each operative
risk factor, and the reduction of the risk of smoking by HRT
cannot be explained by such a position.
The recently proposed altered homeostatic theory (2) provides a
mechanism by which HRT can prevent smoking-induced changes.
This hypothesis asserts that the major risk factors favor disease by
the single mechanism of shifting homeostasis inappropriately
toward defensive action (fight/flight), and that the major factors
that prevent IHD reverse this inappropriate shift. Thus, any
preventative measure (such as HRT) can offset any risk factor (such
as smoking). Most individuals have multiple risk factors, and the
ability of single preventative measures, such as HRT, vitamin E,
exercise and low dose aspirin, to reduce the incidence of IHD in
the general population (3) suggests neutralization of diverse risk
factors by single agents.
The altered homeostatic theory was prompted by a study (3)
that showed that major risk factors for IHD, such as stress,
smoking, abnormal lipids, cocaine, diabetes, obesity and homocys-
teine, each express the combination of spasm of resistance vessels
(S-RV) and a thrombotic tendency (S-RV/clotting), and major
preventative factors, such as HRT, the exercised state, vitamin E
and low dose aspirin, each express the combination of vasodilation
of resistance vessels (V-RV) and an antithrombotic tendency
(V-RV/anticlotting).
That major risk and preventative factors express S-RV/clotting
and V-RV/anticlotting, respectively, seems highly consistent with
risk factors operating by one mechanism that is opposed by
preventative factors. Relating these opposing mechanisms to shifts
of homeostasis was based on multiple factors. In brief, the idea of
altered homeostasis was derived from the S-RV concept of
ischemic diseases (3,4), which attributes symptoms to S-RV and
S-RV to altered vascular homeostasis. For the altered homeostatic
theory, alterations of homeostasis were extended to involve other
components of homeostasis, such as the autonomic nervous system
and metabolic processes. In Teede et al.’s study, HRT improved
cholesterol, intimal carotid thickening and systemic arterial com-
pliance, which is consistent with improvement of multiple body
functions.
The idea of an altered homeostatic balance was derived from the
opposition of the autonomic nervous system (sympathetic nervous
system defensive fight/flight vs. parasympathetic nervous system
conservation/withdrawal). The association of sympathetic hyper-
activity with multiple risk factors (2) and the expression of
S-RV/clotting by the alpha-sympathetic nervous system (2) led to
relating the homeostatic shift with inappropriate fight/flight. Also
helpful was Selye’s idea (5) that stress favors disease by prompting
an imbalance of homeostasis with overactivity of the defensive
sympathetic fight/flight response (2). Further, the significant
involvement of inflammation—a basic homeostatic defense mech-
anism—in IHD (2,6,7) strengthened the idea that risk factors shift
homeostasis toward defensive action.
The possibility that any preventative measure operates against
any risk factor has enormous implications for the prevention of
IHD. For example, risk factors that are impossible or difficult to
correct, such as age, smoking, diabetes and obesity, could be
treated by preventative agents, such as HRT (in postmenapausal
women), exercise, vitamin E and low dose aspirin.
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REPLY
The hypothesis generated by Hellstrom in his letter proposes that
estrogen negates the vasoconstrictive and prothrombotic changes
induced by cardiovascular risk factors (CVRFs), including smok-
ing. The concept that CVRFs act by altering the vasoconstrictive/
vasodilative balance toward vasoconstriction, with increased spasm
of resistance vessels, and that estrogen may reverse this balance, is
plausible. However, we suggest that estrogen shifts the balance
between fibrinolytic and coagulation systems toward a prothrom-
botic state.
Smoking impairs endothelial function, alters lipid oxidation and
increases intima medial thickness (IMT) and atherosclerosis.
Alternatively, estrogen reduces the impact of CVRFs, including
smoking, by improvement in lipid profiles, lipoprotein oxidation,
endothelial function, and reduction in coronary intimal plaque and
proliferation of vascular smooth muscle. We have previously
demonstrated that estrogen also negates age-related deterioration
in arterial structure (IMT) and function (1), an effect more marked
in high risk smokers (2). For Hellstrom’s hypothesis to hold true,
the benefits of estrogen directly on the vessel wall would be
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mediated through a reduction in spasm of the resistance vessels,
which is possible. Yet this does not address the obstructive effects
of atherosclerotic plaque, nor the important influence of large
artery biomechanical properties (compliance).
The suggestion that the cardiovascular effects of estrogen
therapy are mediated through antithrombotic effects is more
difficult to justify, however. To date, the only controlled interven-
tional trial based on cardiovascular outcomes is the large, well-
designed, secondary prevention Heart and Estrogen-progestin
Replacement Study (HERS) (3). Despite a wealth of previous data
suggesting individual mechanisms of cardioprotection with HRT,
no net clinical benefit was observed. Rather, an early increase in
both arterial vascular and venous thrombotic events was associated
with HRT, potentially mediated by the prothrombotic effect of
combined HRT. In keeping with this, in a recent controlled trial
of combined oral HRT, we demonstrated coagulation activation
with generation of both thrombin and fibrin (4). Although
concomitant secondary activation of fibrinolysis was observed, a
shift toward a prothrombotic state was suggested. The majority of
studies on coagulation have also noted adverse procoagulant effects
of HRT. We cannot agree that estrogen reduces the effects of
smoking by antithrombotic mechanisms, and we suggest instead
that the prothrombotic effects of estrogen may serve to neutralize
the beneficial vessel wall effects.
The results of HERS perhaps also serve to emphasise another
vital point. Although estrogen improves individual circulation
characteristics, including arterial compliance and IMT, when
studied in isolation, its effects are diverse and complex, and we
believe it is inappropriate to extrapolate from the study of isolated
mechanisms of estrogen action to the clinical implications of HRT
use. We would agree with the cautionary note expressed in the ac-
companying editorial by O’Grady that observational data should not
be overinterpreted or used alone to dictate clinical management which
should be based on definitive clinical trials. After the HERS results,
it is unlikely that other controlled trials in high risk women will be
initiated. However, a better understanding of the mechanisms of
estrogen action may assist in identifying alternative interventions,
including new selective estrogen modulating agents, with beneficial
actions on the vessel wall, without prothrombotic effects.
Helena Teede, MBBS
Barry McGrath, MD
Department of Medicine
Monash Medical Centre
246 Clayton Road
Melbourne, Australia 3168
PII S0735-1097(99)00620-8
REFERENCES
1. Teede HJ, Liang YL, Shiel LM, et al. Hormone replacement therapy in
postmenopausal women protects against smoking-induced changes in
vascular structure and function. J Am Coll Cardiol 1999;34:131–7.
2. McGrath BP, Liang Yu-Lu, Teede HJ, et al. Age-related deterioration
in arterial structure and function in postmenopausal women: the impact
of hormone replacement therapy. Atheroscler Thromb Vasc Biol
1998;18:1149–56.
3. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus
progestin for secondary prevention of coronary heart disease in post-
menopausal women. JAMA 1998;280:605–13.
4. Peverill R, Teede H, McGrath BP, et al. Hormone replacement therapy
increases coagulation activity, fibrinolytic potential and fibrinolysis
(abstr). Arteriosch Thromb Vasc Biol. In press.
Lack of Effect of Coenzyme Q
on Left Ventricular Function in
Patients With Congestive Heart Failure
The lack of benefit observed by Watson et al. (1) in patients with
advanced congestive heart failure (CHF) treated with 100 mg of
coenzyme Q 10 (CoQ 10) for three months was predictable. This is
a case of too little for too short a time and, most importantly, as the
authors postulate, too late in the course of CHF. The authors’
observations are in keeping with two previous trials similar in
design and duration of therapy.
Permanetter et al. (2) studied 25 patients with advanced idio-
pathic dilated cardiomyopathy with documented normal coronary
anatomy, using 100 mg of CoQ 10 per day for four months, in a
double-blind, crossover study design, and found a similar lack of
significant effect on measurements of myocardial function.
Hofman-Bang et al. (3) studied 79 patients, again using 100 mg of
CoQ 10 daily for three months, this time showing a very slight but
significant improvement in ejection fraction, from 23 6 12% to
25 6 13% (p , 0.05).
In contrast, in a double-blind, crossover trial, Langsjoen et al.
(4) evaluated 19 patients with idiopathic dilated cardiomyopathy
who were much earlier in the course of their disease and showed an
improvement in EF from 44 6 3% to 56 6 10% (p , 0.001) with
three months of treatment with CoQ 10, 100 mg per day.
Although the methodology for myocardial function measurements
in this early controlled trial (impedance cardiography and systolic
time indexes) has been judged “outdated” by Watson et al., the
measurements were nonetheless performed in a blinded fashion by
an experienced laboratory. The largest double-blind, controlled
trial to date by Morisco et al. (5) randomized 641 patients with
CHF to receive either placebo or 2 mg/kg body weight per day of
CoQ 10 for one year. The number of patients requiring hospital
admission for worsening heart failure was significantly lower in the
CoQ 10 group (73 vs. 118, p , 0.001), and episodes of pulmonary
edema were significantly lower (20 vs. 51, p , 0.001). Thus, a
higher dose of CoQ 10 for a longer period showed a highly
significant benefit. In a meta-analysis spanning the years of 1986 to
1995, Soja and Mortensen (6) reviewed 14 controlled trials of
patients with CHF who were treated with CoQ 10 in 60 to
200 mg/day doses as a supplement to conventional treatment.
Eight of the 14 controlled trials met the authors’ inclusion criteria
for reliable meta-analysis, with seven of the eight studies docu-
menting significant improvement in different variables of heart
function in patients with CHF of varying etiology (idiopathic
dilated cardiomyopathy, ischemic heart disease, hypertension,
valvular heart disease and congenital heart disease). Specifically,
significant improvements in stroke volume, ejection fraction,
cardiac output, cardiac index and end-diastolic volume were
observed with CoQ 10 treatment.
The findings by Watson et al. (1), Permanetter et al. (2) and
Hofman-Bang et al. (3) are in keeping with the clinical observa-
tions of cardiologists who have had extensive practical experience
with the use of this supplement in patients with advanced dilated
cardiomyopathies. The most dramatic improvements in myocar-
dial function have been observed in those patients fortunate
enough to have been treated with supplemental CoQ 10 shortly
after the diagnosis of CHF, before the development of irreversible
myocyte loss and fibrosis. Although the optimal dose of CoQ 10 in
the treatment of CHF has not been established, it has become
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